U.S. Attorney Probes Bristol-Myers For Securities Fraud

Law360, New York (October 26, 2006, 12:00 AM EDT) -- An ongoing investigation into corporate governance issues at Bristol-Myers Squibb Co. by the Office of the U.S. Attorney for the District of New Jersey has been broadened to include a probe into whether or not the company violated federal securities laws.

The U.S. attorney’s inquiries regarding both corporate governance and securities laws center on the proposed settlement between Bristol-Myers Squibb Co., Sanofi-Aventis and Canadian generic drug maker Apotex Inc. that would have forestalled the entry of a generic version of BMS’ blockbuster blood-thinning drug Plavix until...
To view the full article, register now.